Funder: National Institutes of Health
Due Dates: February 8, 2027 (Estimated, forecasted)
Funding Amounts: UH2/UH3 up to 5 years; standalone UH3 up to 3 years; award ceiling not specified
Summary: Supports validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, and treatment decision-making.
Key Information: This is a forecasted opportunity; details may change—check program page for updates.